Maof climbs 0.7%

To 1,208.54, biggest gain since April 14 as Tel Aviv Sunday trading closes.

April 26, 2010 09:50
The Jerusalem Post

TA stock exchange 224 88. (photo credit: Bloomberg)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


The TA-25 Index advanced 0.7 percent, the biggest gain since April 14, to 1,208.54 at the close in Tel Aviv on Sunday. Investors traded about NIS 1.46 billion in shares and convertible securities.

Bio Light Israeli Life Sciences advanced 10% after its Zetiq Technologies unit signed an agreement with China’s Biomics Biotechnologies to cooperate in conducting clinical tests.

D-Pharm, a biopharmaceutical company, retreated 1.2% after saying it was weighing the possibility of raising NIS 23 million to fund the development of a treatment for migraines, epilepsy and bipolar disorder.

Delek Group, an energy and real-estate holding company, rose 1.7% after its Delek US Holdings unit was rated new “sector perform” at RBC Capital Markets.

Micromedic Technologies, a biomedical development company, climbed 5.2% after saying it had begun testing its kit for the early diagnosis of colon cancer to receive CE Mark approval to market the product in Europe.

Procognia Israel, a developer of tools for analyzing sugars in proteins, surged 19% after saying the first trial in a joint research project with Seahorse Bioscience Inc. had been successful.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection